Ki16198LPA antagonist CAS# 355025-13-7 |
- AM966
Catalog No.:BCC1355
CAS No.:1228690-19-4
- AM-095 free base
Catalog No.:BCC1352
CAS No.:1228690-36-5
- AM095
Catalog No.:BCC1351
CAS No.:1345614-59-6
- Ki16425
Catalog No.:BCC1155
CAS No.:355025-24-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 355025-13-7 | SDF | Download SDF |
| PubChem ID | 9913405 | Appearance | Powder |
| Formula | C24H25ClN2O5S | M.Wt | 488.98 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | methyl 3-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-1,2-oxazol-5-yl]phenyl]methylsulfanyl]propanoate | ||
| SMILES | CC1=NOC(=C1NC(=O)OC(C)C2=CC=CC=C2Cl)C3=CC=C(C=C3)CSCCC(=O)OC | ||
| Standard InChIKey | HHVJBROTJWPHHX-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C24H25ClN2O5S/c1-15-22(26-24(29)31-16(2)19-6-4-5-7-20(19)25)23(32-27-15)18-10-8-17(9-11-18)14-33-13-12-21(28)30-3/h4-11,16H,12-14H2,1-3H3,(H,26,29) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Ki16198 Dilution Calculator
Ki16198 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0451 mL | 10.2254 mL | 20.4507 mL | 40.9015 mL | 51.1268 mL |
| 5 mM | 0.409 mL | 2.0451 mL | 4.0901 mL | 8.1803 mL | 10.2254 mL |
| 10 mM | 0.2045 mL | 1.0225 mL | 2.0451 mL | 4.0901 mL | 5.1127 mL |
| 50 mM | 0.0409 mL | 0.2045 mL | 0.409 mL | 0.818 mL | 1.0225 mL |
| 100 mM | 0.0205 mL | 0.1023 mL | 0.2045 mL | 0.409 mL | 0.5113 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ki16198 is the methyl ester of Ki16425, which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 0.34 μM and 0.93 μM, respectively, shows weaker inhibition for LPA2, no activity at LPA4, LPA5, LPA6.
- TCS 1205
Catalog No.:BCC7819
CAS No.:355022-97-8
- 3-beta-O-(trans-p-Coumaroyl)maslinic acid
Catalog No.:BCN1452
CAS No.:35482-91-8
- Balicatib
Catalog No.:BCC5139
CAS No.:354813-19-7
- SC-514
Catalog No.:BCC4554
CAS No.:354812-17-2
- Corianin
Catalog No.:BCN5296
CAS No.:35481-77-7
- Hirsuteine
Catalog No.:BCN2756
CAS No.:35467-43-7
- Caraphenol A
Catalog No.:BCN5295
CAS No.:354553-35-8
- INO-1001
Catalog No.:BCC2212
CAS No.:3544-24-9
- Bendamustine HCl
Catalog No.:BCC1153
CAS No.:3543-75-7
- 5-[Bis(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazole-2-butanoic acid ethyl ester
Catalog No.:BCC8724
CAS No.:3543-74-6
- 1-Methyl-5-amino-1H-benzimidazole-2-butanoic acid ethyl ester
Catalog No.:BCC8469
CAS No.:3543-73-5
- 1-Methyl-5-nitro-1H-benzimidazole-2-butanoic acid ethyl ester
Catalog No.:BCC8470
CAS No.:3543-72-4
- Ki16425
Catalog No.:BCC1155
CAS No.:355025-24-0
- 6'-O-p-Hydroxybenzoylcatalposide
Catalog No.:BCN5297
CAS No.:355143-38-3
- YM-155 hydrochloride
Catalog No.:BCC2066
CAS No.:355406-09-6
- Buflomedil HCl
Catalog No.:BCC4760
CAS No.:35543-24-9
- N,N-dimethyl-2-Quinoxalinamine
Catalog No.:BCC9066
CAS No.:35552-76-2
- tert-Butyl rosuvastatin
Catalog No.:BCC9163
CAS No.:355806-00-7
- Betmidin
Catalog No.:BCN8253
CAS No.:35589-22-1
- Fluocinonide
Catalog No.:BCC4953
CAS No.:356-12-7
- Darapladib
Catalog No.:BCC1515
CAS No.:356057-34-6
- Toceranib
Catalog No.:BCC2005
CAS No.:356068-94-5
- N-Desethyl Sunitinib
Catalog No.:BCC1792
CAS No.:356068-97-8
- CP 20961
Catalog No.:BCC6063
CAS No.:35607-20-6
Modulation of Nav1.8 by Lysophosphatidic Acid in the Induction of Bone Cancer Pain.[Pubmed:27631681]
Neurosci Bull. 2016 Oct;32(5):445-54.
Given that lysophosphatidic acid (LPA) and the tetrodotoxin-resistant sodium channel Nav1.8 are both involved in bone cancer pain, the present study was designed to investigate whether crosstalk between the LPA receptor LPA1 (also known as EDG2) and Nav1.8 in the dorsal root ganglion (DRG) contributes to the induction of bone cancer pain. We showed that the EDG2 antagonist Ki16198 blocked the mechanical allodynia induced by intrathecal LPA in naive rats and attenuated mechanical allodynia in a rat model of bone cancer. EDG2 and Nav1.8 expression in L4-6 DRGs was upregulated following intrathecal or hindpaw injection of LPA. EDG2 and Nav1.8 expression in ipsilateral L4-6 DRGs increased with the development of bone cancer. Furthermore, we showed that EDG2 co-localized with Nav1.8 and LPA remarkably enhanced Nav1.8 currents in DRG neurons, and this was blocked by either a protein kinase C (PKC) inhibitor or a PKCepsilon inhibitor. Overall, we demonstrated the modulation of Nav1.8 by LPA in DRG neurons, and that this probably underlies the peripheral mechanism by which bone cancer pain is induced.
The Role of Lysophosphatidic Acid on Airway Epithelial Cell Denudation in a Murine Heterotopic Tracheal Transplant Model.[Pubmed:27500235]
Transplant Direct. 2015 Oct 19;1(9):e35.
BACKGROUND: Chronic rejection is the major leading cause of morbidity and mortality after lung transplantation. Obliterative bronchiolitis (OB), a fibroproliferative disorder of the small airways, is the main manifestation of chronic lung allograft rejection. However, there is currently no treatment for the disease. We hypothesized that lysophosphatidic acid (LPA) participates in the progression of OB. The aim of this study was to reveal the involvement of LPA on the lesion of OB. METHODS: Ki16198, an antagonist specifically for LPA1 and LPA3, was daily administered into the heterotopic tracheal transplant model mice at the day of transplantation. At days 10 and 28, the allografts were isolated and evaluated histologically. The messenger RNA levels of LPAR in microdissected mouse airway regions were assessed to reveal localization of lysophosphatidic acid receptors. The human airway epithelial cell was used to evaluate the mechanism of LPA-induced suppression of cell adhesion to the extracellular matrix (ECM). RESULTS: The administration of Ki16198 attenuated airway epithelial cell loss in the allograft at day 10. Messenger RNAs of LPA1 and LPA3 were detected in the airway epithelial cells of the mice. Lysophosphatidic acid inhibited the attachment of human airway epithelial cells to the ECM and induced cell detachment from the ECM, which was mediated by LPA1 and Rho-kinase pathway. However, Ki16198 did not prevent obliteration of allograft at day 28. CONCLUSIONS: The LPA signaling is involved in the status of epithelial cells by distinct contribution in 2 different phases of the OB lesion. This finding suggests a role of LPA in the pathogenesis of OB.
Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo.[Pubmed:22348348]
Cancer Sci. 2012 Jun;103(6):1099-104.
Pancreatic cancer is highly metastatic and has a poor prognosis. However, there is no established treatment for pancreatic cancer. Lysophosphatidic acid (LPA) has been shown to be present in effluents of cancers and involved in migration and proliferation in a variety of cancer cells, including pancreatic cancer cells, in vitro. In the current study, we examined whether an orally active LPA antagonist is effective for pancreatic cancer tumorigenesis and metastasis in vivo. Oral administration of Ki16198, which is effective for LPA(1) and LPA(3), into YAPC-PD pancreatic cancer cell-inoculated nude mice significantly inhibited tumor weight and remarkably attenuated invasion and metastasis to lung, liver, and brain, in association with inhibition of matrix metalloproteinase (MMP) accumulation in ascites in vivo. Ki16198 inhibited LPA-induced migration and invasion in several pancreatic cancer cells in vitro, which was associated with the inhibition of LPA-induced MMP production. In conclusion, Ki16198 is a promising orally active LPA antagonist for inhibiting the invasion and metastasis of pancreatic cancer cells. The inhibitory effects of the antagonist on invasion and metastasis in vivo may be partially explained by the inhibition of motility activity and MMP production in cancer cells.
